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Fetal-Derived Trophoblast Use the Apoptotic Cytokine
Tumor Necrosis Factor-–Related Apoptosis-Inducing
Ligand to Induce Smooth Muscle Cell Death
Rosemary J. Keogh, Lynda K. Harris, Abigail Freeman, Philip N. Baker, John D. Aplin,
Guy StJ. Whitley, Judith E. Cartwright
Abstract—Remodeling of the uterine spiral arteries during pregnancy transforms them from high to low resistance vessels
that lack vasoconstrictive properties. This process is essential to meet the demand for increased blood flow imposed by
the growing fetus. Loss of endothelial and smooth muscle cells (SMC) is evident in remodeled arteries but the
mechanisms underlying this transformation remain unknown. This study investigated the hypothesis that fetal
trophoblast invading from the placenta instigate remodeling by triggering cell death in vascular SMC. Specifically, a
role for trophoblast-derived death inducing cytokine tumor necrosis factor-–related apoptosis-inducing ligand (TRAIL)
was investigated. Expression of the activating TRAIL receptors R1 and R2 was detected by flow cytometry on human
aortic SMC and by immunohistochemistry on spiral artery SMC. Recombinant human TRAIL induced human aortic
SMC apoptosis, which was inhibited by antibodies against TRAIL-R1 or -R2. Perfusion of denuded spiral artery
segments with recombinant human TRAIL also induced SMC apoptosis. Trophoblasts isolated from first trimester
placenta expressed membrane-associated TRAIL and induced apoptosis of human aortic SMC; apoptosis was
significantly inhibited by a recombinant human TRAIL-R1:Fc construct. Trophoblast within the first trimester placental
bed also expressed TRAIL. These data show that: 1) TRAIL causes SMC death; 2) trophoblast produce the apoptotic
cytokine TRAIL; and 3) trophoblast induce SMC apoptosis via a TRAIL-dependent mechanism. We conclude that
TRAIL produced by trophoblast causes apoptosis of SMC and thus may contribute to SMC loss during spiral artery
remodeling in pregnancy. (Circ Res. 2007;100:834-841.)
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Remodeling of the uterine spiral arteries commencesduring the first trimester of human pregnancy and is
completed by around 20 weeks of gestation. During this time,
vessels lose their vaso-responsiveness because of loss of
endothelial and smooth muscle cells (SMC), which are
replaced with fetal-derived trophoblast in a fibrinoid matrix.
This process, termed physiological change, results in trans-
formation of the vessels from narrow to large calibre conduits
and is essential to enable the oxygen and nutrient demands of
the growing fetus to be met.1 Histological evidence suggests
a role for trophoblast in this process, as shallow trophoblast
invasion and incomplete remodeling have been associated
with fetal growth restriction,2 early onset of labor3 and
pre-eclampsia.4,5
The mechanisms underlying spiral artery remodeling are
still yet to be elucidated, largely because of the difficulty in
obtaining tissue and the scarcity of suitable animal models
that mirror the highly invasive nature of human hemochorial
placentation.1,6 Much of the current understanding is derived
from examination of histological specimens and studies of
primate models. Trophoblast, derived from chorionic villi,
migrate away from the placental villous tips forming a
population termed extravillous trophoblast. These cells form
two populations, defined by the route with which they invade
the surrounding tissue. Interstitial trophoblast invade the
decidual stroma, migrate across the endometrial-myometrial
boundary and progress into the first third of the myometrium.
Endovascular trophoblast invade via the lumens of spiral
arteries, however the source of these cells is unclear. Al-
though it is possible that they may enter the vessel lumen
directly and migrate against the flow of blood, it is more
likely that they arise from an interstitial population that
intravasate into the artery lumen.7,8 By adopting a vascular-
like phenotype extravillous trophoblast are able to infiltrate
the spiral arteries and interact with cells of the vessel walls.9
We have shown that endothelial cells and smooth muscle
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cells are lost from spiral arteries by trophoblast-induced
apoptosis through a mechanism involving activation of the
Fas/Fas ligand (FasL) pathway.10,11 The aim of this study was
to investigate other apoptotic ligands produced by trophoblast
that may be involved in causing apoptosis of SMC in the
vessel wall.
Tumor necrosis factor (TNF)-–related, apoptosis-
inducing ligand (TRAIL) is a member of the TNF family of
death-promoting ligands. It is expressed on the surface of
cells in a membrane bound form, the carboxy-terminus of
which can be cleaved by cysteine proteases generating a
soluble form.12,13 TRAIL is known to be produced by the
placenta, and mRNA for TRAIL was upregulated in two
trophoblast cell lines following cytokine stimulation.14–16
TRAIL transduces its apoptotic signal via receptor trimeriza-
tion and activation of the extrinsic pathway of apoptosis. The
adaptor molecule Fas-associated death domain (FADD) binds
to the intracellular death domain (DD) of the clustered
receptors and recruits and activates caspase-8, which initiates
activation of the caspase cascade leading to apoptosis (re-
viewed in13,17,18).
TRAIL signaling is made more complex by the existence
of five different receptors: TRAIL-receptor 1 (TRAIL-R1)
and TRAIL-receptor 2 (TRAIL-R2) contain intracellular DDs
and can signal to cause apoptosis; TRAIL-receptor 3
(TRAIL-R3) lacks a DD, and TRAIL-receptor 4 (TRAIL-R4)
has a truncated DD, neither of which can signal and are
thought to act as decoy receptors; and finally a fifth, soluble
receptor, osteoprotegerin, can bind and sequester TRAIL,
although its importance in regulating TRAIL signaling is yet
to be clearly defined.13,19 Despite the initial theory that the
relative expression of activating and decoy receptors may
determine a cell’s susceptibility to TRAIL-induced apoptosis,
no such link has been definitively demonstrated.18
Much interest in TRAIL has arisen from the observation
that TRAIL appears to selectively induce apoptosis in tumor
or transformed cells, with no apparent effect on normal cells.
This led to many studies examining the potential of using
TRAIL in cancer treatment, exploiting two sought after
attributes of selectivity and low toxicity compared with other
pro-apoptotic cytokines such as FasL or TNF-.17,20,21 How-
ever, TRAIL has been found to induce apoptosis in normal
human hepatocytes22 and normal human prostate epithelial
cells,23 and its effects appear not only cell but species
specific.19,21 Indeed, many normal human cells express the
activating receptors TRAIL-R1 and TRAIL-R2,24,25 suggest-
ing TRAIL may have physiological roles under normal
conditions.
The effects of TRAIL on vascular cells have not been
extensively investigated. Both endothelial26 and SMC27 have
been shown to express TRAIL receptors, and survival and
proliferation of both cell types has been reported to be
stimulated by TRAIL.27,28 In direct contrast, TRAIL has also
been found to induce apoptosis of endothelial cells26 and
SMC.29 A recent article has demonstrated that vascular SMC
in atherosclerotic plaques are killed by TRAIL-expressing T
cells.30 Clear delineation of the impact of TRAIL on the
vasculature is thus warranted, particularly given this recent
interest in its role in atherosclerotic plaque stability.
This study examines the hypothesis that vascular SMC
apoptosis plays a key step in remodeling uterine spiral
arteries during human pregnancy. Specifically, we focused on
the interaction between trophoblast and SMC, and the poten-
tial involvement of TRAIL in trophoblast-induced SMC
apoptosis. Our results define a physiological role for TRAIL
during pregnancy and identify a mechanism that contributes
to SMC loss during vessel remodeling. This finding has major
implications for both the mechanism of vessel remodeling in
normal pregnancy and for the pathogenesis of pregnancy
complications such as pre-eclampsia and fetal growth
restriction.
Materials and Methods
Reagents
Full details of reagents used are provided in the online data
supplement available at http://circres.ahajournal.org.
Tissue, Cell Culture, and Labeling
Informed consent was obtained for all myometrial and placental
tissue used in this study and ethical committee approval was in place.
Normal first trimester placenta and decidua (8 to 13 weeks) was
obtained at elective surgical termination of pregnancy. Term decid-
ual/myometrial biopsies taken from nonplacental bed tissue were
obtained from women with normal pregnancies at elective caesarean
section. Isolation and culture of first trimester primary cytotropho-
blast (CTB), and culture and labeling of human aortic SMC
(HASMC) are described in the online data supplement.
Time-Lapse Microscopy
Apoptosis was monitored by time-lapse microscopy as described
previously.10,11 Images were analyzed using ImagePro Plus (Media
Cybernetics, Silver Spring, Md). Details are provided in the online
data supplement.
Immunoblotting
Preparation of HASMC lysates for analysis of cleaved PARP
expression is described in the online data supplement.
Preparation of Spiral Artery Sections
Dissection of spiral arteries was performed as previously de-
scribed.10,11,31 Details are provided in the online data supplement.
Immunohistochemistry
Details of cell and tissue staining and microscopic analysis are
provided in the online supplement.
Flow Cytometry
Flow cytometric analysis of TRAIL expression on trophoblast and
TRAIL receptor expression on HASMC is described in the online
supplement. Data were analyzed using WinMDI 2.8 freeware
(http://facs.scipps.edu/software.html).
Vessel Explant Model
Dissection and perfusion of spiral arteries was performed as previ-
ously described.10,11,31 Details are provided in the online data
supplement.
TUNEL Staining
TUNEL staining of tissue sections was performed as previously
described.10 Details are provided in the online data supplement.
Measurement of TRAIL Expression
Lysates and medium from primary CTB were analyzed for TRAIL,
as described in the online data supplement.
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Statistics
Data were compared using either a repeated measures ANOVA or
paired t test (parametric) or a Kruskal-Wallis test (nonparametric).
Appropriate posthoc tests were applied and all statistical analyses
performed using GraphPad Prism software, version 4 (GraphPad
Software, San Diego, Calif). Significance was taken as P0.05. Data
are presented as the meanSEM from at least 3 independent exper-
iments.
Results
TRAIL Induces Smooth Muscle Cell Death
To investigate whether TRAIL can induce death of SMC,
cultures of HASMC were treated with rhTRAIL and apopto-
sis was assessed. Using time-lapse microscopy, images of the
cells were taken at 15 minute intervals over 65 hours. The
time of onset of apoptosis, characterized by the first appear-
ance of apoptotic morphology, was scored for 40 individual
cells and a cumulative time course of apoptosis was derived.
Recombinant human TRAIL (rhTRAIL) instigated apoptosis
of the cells in a concentration-dependent manner over 65
hours (Figure 1A). The percent apoptotic cells at 60 hours
was significantly increased by rhTRAIL at concentrations of
0.01 g/mL and above (Figure 1B).
To confirm cell death in response to TRAIL occurred by
apoptosis, HASMC cultures treated with rhTRAIL were
lyzed and analyzed by immunoblotting for the expression of
cleaved poly(ADP-ribose) polymerase (PARP), a marker of
apoptosis. Following 24 or 60 hours treatment with 0.1
g/mL rhTRAIL, a significant increase in cleaved PARP
protein was observed (Figure 2A). To further verify that cell
death was apoptotic, time-lapse analysis of rhTRAIL-treated
cells was repeated in the presence of the pan caspase inhibitor
zVAD-fmk. As caspases are central in the execution of
programmed cell death, blocking caspase activation should
rescue cells from apoptosis. After 60 hours treatment with
rhTRAIL (0.5 g/mL), the percent apoptotic HASMC was
significantly increased. This increase was significantly inhib-
ited by zVAD-fmk (Figure 2B). This data provides further
evidence to suggest that HASMC death in response to
rhTRAIL occurs via apoptosis.
Receptor Expression and Involvement in
TRAIL-Induced Apoptosis
TRAIL binds to five different receptors, two of which
transduce an apoptotic signal. To investigate which receptors
were involved in activating rhTRAIL-induced HASMC apo-
ptosis, TRAIL-R1 and TRAIL-R2 expression on HASMC
was first confirmed by flow cytometry (Figure 3A and B).
Time-lapse microscopy was then used to assess HASMC
apoptosis in the presence of antibodies that blocked activation
of these receptors. Following stimulation with rhTRAIL (0.25
g/mL) for 60 hours, HASMC apoptosis was significantly
increased. In the presence of an antibody blocking either
TRAIL-R1 or TRAIL-R2, rhTRAIL-induced apoptosis was
significantly inhibited (Figure 3C and 3D, respectively). This
indicates that both TRAIL-R1 and TRAIL-R2 are expressed
on HASMC and that both are involved in apoptotic signaling.
As this study focuses on a role for TRAIL in vessel
remodeling during pregnancy, it was necessary to demon-
strate that receptors for TRAIL are expressed on spiral artery
SMC in situ. Sections of first trimester decidua containing
unmodified spiral arteries were stained using antibodies
against TRAIL-R1 and -R2. Expression of both receptors was
noted on a subset of spiral artery SMC (Figure 4A, B);
receptor expression was also evident in the decidual stroma.
Immunohistochemistry performed using an antibody against
TRAIL indicated that first trimester extravillous trophoblast
express this ligand in vivo (Figure 4C and 4D). These
findings clarify that receptors for TRAIL are expressed on
SMC in the placental bed, during the window when spiral
artery remodeling takes place. At the same time, TRAIL-
expressing trophoblasts are present within the decidua.
The Role of the Trophoblast in SMC Apoptosis
The aim of this work was to examine interactions between
trophoblast and vascular cells, specifically SMC, to deter-
mine the role that trophoblast play in the loss of SMC
during remodeling. By monitoring primary first trimester
human cytotrophoblast (CTB) and HASMC cocultures by
time-lapse microscopy, it was possible to examine these
interactions.
Figure 1. HASMC death is induced by rhTRAIL. HASMC were
monitored by time-lapse microscopy and the time point at
which cells underwent apoptosis was scored. A, Time course of
HASMC apoptosis following stimulation with rhTRAIL: control
(F), 0.001 g/mL (▫), 0.01 g/mL (ƒ), 0.1 g/mL (). B, % apo-
ptotic HASMC at 60 hours, *P0.05 and **P0.01, Kruskal-
Wallis test, Dunn’s posthoc test (meanSEM, n4).
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A typical time-lapse sequence, highlighting a small seg-
ment of the total field of view, is shown in the accompanying
video (http://circres.ahajournal.org). Six single images taken
from this sequence are shown in Figure 5. It is apparent that
direct contact is made between the two cell types, and that the
primary CTB instigates this interaction (0 to 3 hours). As the
primary CTB moves away (3 to 9 hours), a thin attachment
extrudes out between the cells, indicated by the arrow. The
HASMC then undergoes apoptosis, with a classic apoptotic
blister forming after the primary CTB has departed (9 to 12
hours). Immunohistochemical staining of a parallel experi-
ment using antibodies against smooth muscle actin (HASMC;
red) and cytokeratin 7 (CTB; green) is also shown (Figure
5B–D). The time-lapse video sequence demonstrates that
HASMC undergo apoptosis following interactions initiated
by CTB, and that direct cell contact between the two cell
types may be an important component of this process.
Time-lapse microscopy provides visual evidence for the
involvement of CTB in HASMC apoptosis. Quantitative
analysis of these sequences involved scoring the onset of
apoptosis of HASMC in the presence or absence of primary
Figure 2. TRAIL-induced HASMC death occurs by apoptosis. A,
Cultures of HASMC were treated with rhTRAIL (0.01 or 0.1
g/mL) and apoptosis was assessed at 24 and 60 hours by im-
munoblot analysis of cleaved PARP expression. A representative
auto-radiograph is shown. The bar chart shows the pooled den-
sitometric data, *P0.001, repeated measures ANOVA, Bonfer-
roni’s post-hoc test (meanSEM, n3). B, HASMC were treated
with rhTRAIL (0.5 g/mL) in the presence or absence of zVAD-
fmk (50 mol/L) and monitored by time-lapse microscopy. The
time point at which cells underwent apoptosis was scored. %
apoptotic HASMC at 60 hours is shown, *P0.001, repeated
measures ANOVA, Bonferroni’s posthoc test (meanSEM, n4).
Figure 3. Expression of TRAIL receptors on HASMC and the
effect of blocking TRAIL receptors on rhTRAIL-induced apopto-
sis. A and B, TRAIL receptor expression on HASMC assessed
by flow cytometry. The histograms show unpermeablized cells
labeled with isotype control IgG (gray shading) and (A) anti-
TRAIL-R1 (open histogram) or (B) anti-TRAIL-R2 (open histo-
gram). C and D, HASMC were monitored by time-lapse micros-
copy and the time point at which cells underwent apoptosis was
scored. Shown is % apoptotic HASMC at 60 hours following
stimulation with rhTRAIL (0.25 g/mL) in the presence or
absence of either (C) TRAIL-R1 blocking antibody (5 g/mL) or
(D) TRAIL-R2 blocking antibody (5 g/mL). *P0.01 and
**P0.001, repeated measures ANOVA, Bonferroni’s posthoc
test (meanSEM, n3).
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CTB. The addition of primary CTB resulted in an increase in
the rate of HASMC apoptosis over a 65 hour time course
(Figure 6A). Comparison of the percent apoptotic cells at 60
hours shows a significant increase in HASMC apoptosis in
the presence of primary CTB (Figure 6B).
Having demonstrated that the presence of primary CTB
is sufficient to increase HASMC apoptosis, the involve-
ment of TRAIL in this process was investigated. A
construct consisting of the extracellular domain of recom-
binant human TRAIL-R1 (amino acids 24 to 239) fused to
the Fc portion of human IgG1 (rhTRAIL-R1:Fc) was used.
The construct acts as a soluble receptor and binds all
ligand (both soluble and membrane attached), thus pre-
venting TRAIL from interacting with any of its receptors
and inhibiting TRAIL-induced apoptosis. When this con-
struct was added in time-lapse experiments to cocultures of
HASMC, primary CTB-induced HASMC apoptosis was
inhibited (Figure 6A). The percent of apoptotic HASMC in
cocultures with primary CTB at 60 hours was significantly
reduced following the addition of rhTRAIL-R1:Fc (Figure
6B). This provides persuasive evidence that TRAIL is
involved in primary CTB-induced HASMC apoptosis.
TRAIL Production by Trophoblast
The data presented here suggest that SMC death is instigated
by trophoblast by a mechanism involving the apoptotic
cytokine TRAIL, however, the source of this cytokine is
unclear. TRAIL may be produced by the trophoblast, or may
originate from the SMC in an autocrine manner, possibly in
response to a trophoblast-derived signal. In SMC monocul-
tures, the rate of apoptosis was not significantly altered in the
presence of the TRAIL-R1:Fc blocking construct or antibod-
ies against TRAIL-R1 or R2, indicating that SMC-derived
TRAIL does not contribute to basal SMC apoptosis in our
system (% apoptotic cells at 60 hours: 26.73.6 (control)
versus 25.02.5 (TRAIL-R1:Fc), 28.32.2 (TRAIL-R1),
40.04.3 (TRAIL-R2), NS, n3). Furthermore, immunoblot
analysis of HASMC lysates derived from noncontact cocul-
tures with primary CTB showed no change in TRAIL
expression (Figure 6C), and levels of TRAIL in the same
SMC lysates, quantified by ELISA, were below the level of
detection (detection limit 62.5 pg/mL). This data suggests
that CTB do not stimulate TRAIL production by SMC.
We next sought to confirm that trophoblasts produce TRAIL.
Cell lysates made from first trimester primary CTB cultured on
Matrigel for 72 hours contained TRAIL in significant amounts,
when measured by ELISA (572.4160.3 pg TRAIL/mg protein,
n10). No TRAIL was detected in the medium collected from
these cells. This suggested that TRAIL was expressed as the
cell-associated form, rather than being cleaved and released in
soluble form. To confirm this, flow cytometric analysis was
performed on primary CTB cultured for 48 hours on Matrigel.
Nonpermeablized first trimester primary CTB expressed TRAIL
on the cell surface, confirming its presence as the membrane-
bound form of this cytokine (Figure 6D).
TRAIL Causes SMC Apoptosis in Spiral Arteries
Having demonstrated using in vitro systems that SMC
undergo apoptosis in response to either recombinant- or
cell-derived TRAIL, we wished to confirm that the SMC
present in spiral arteries were similarly sensitive to
TRAIL-induced apoptosis. Denuded spiral arteries dis-
sected from nonplacental bed biopsies were perfused with
TRAIL (0.5 g/mL), tied off and cultured for 24 hours.
Vessels were fixed, sectioned and colabeled with TUNEL
to detect apoptosis, and an antismooth muscle actin pri-
mary antibody to visualize SMC. Control vessels showed
limited TUNEL-positive staining in the smooth muscle
layers (Figure 7A, green staining), however, in vessels
Figure 4. TRAIL and its receptors are expressed in first trimes-
ter placental bed tissue. Sections of wax-embedded first trimes-
ter decidua immunostained with antibodies against (A) TRAIL-
R1, (B) TRAIL-R2, (C) TRAIL or (D) cytokeratin-7 (brown).
Sections are counterstained with hematoxylin (blue). A and B,
11 weeks gestation; ˜ indicates positive cells. C and D, 12
weeks gestation. Pictures are representative of n3 indepen-
dent experiments.
Figure 5. Apoptosis of a smooth muscle cell
in the presence of primary CTB. A, Still pic-
tures taken from a sequence of images of a
coculture of primary trophoblast (CTB) and
smooth muscle cells (SMC) 0 to 3 hours.
Primary CTB approaches and interacts with
SMC. 3 to 9 hours, trophoblast moves away.
A thin attachment is visible (indicated by3).
9 to 12 hours; SMC undergoes apoptosis. A
characteristic apoptotic blister is seen (indi-
cated by4). B–D, Immunohistochemical
staining shows SMC staining positive for
smooth muscle actin (red) and primary CTB
staining positive for cytokeratin 7 (green). E,
IgG control.
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treated with TRAIL, significant apoptosis was observed in
the smooth muscle layers (Figure 7B, C). Some TUNEL-
positive staining was observed in the outer connective
tissue of TRAIL-treated vessels, which may have been
caused by disruption of the tissue architecture during
dissection. Alternatively, apoptosis may have been in-
duced in these cells by TRAIL-containing perfusate leak-
ing into the bath before the ends of the vessels are tied off.
To avoid the risk of contamination, control vessels are
always perfused before the treated vessels. These data
confirm that SMC present in the uterine spiral arteries are
indeed susceptible to TRAIL-induced apoptosis, and sup-
port the role of trophoblast-derived TRAIL as a mediator
of vascular SMC loss during spiral artery remodeling.
Discussion
In human pregnancy, the presence of the invading fetal
trophoblast is a critical element that determines the outcome
of spiral artery remodeling. Shallow or incomplete tropho-
blast invasion with limited vessel remodeling has been
associated with complications such as preeclampsia,5 pre-
term labor3 and fetal growth restriction.2 Some studies have
focused on defects that lead to adverse outcomes, but little
work has been done to understand the basis of remodeling in
normal pregnancy. We have previously demonstrated that
primary CTB and trophoblast cell lines can initiate endothe-
lial and SMC apoptosis in spiral arteries via the Fas/Fas
ligand pathway, and have proposed that a trophoblast-
dependent apoptotic mechanism contributes to endothelial
and SMC loss during remodeling in pregnancy.10,11 The
current study identifies TRAIL as another important apoptot-
ic ligand produced by trophoblast, that is able to induce SMC
apoptosis. Here we propose that activation of the TRAIL
pathway also contributes to SMC loss during spiral artery
remodeling in human pregnancy. Spiral artery endothelial
cells may also be sensitive to TRAIL-induced apoptosis;
indeed, a previous study has shown that endothelial cells
express the activating TRAIL receptors.28 Although not
addressed in the current study, we have preliminary data
showing that a human umbilical vein endothelial cell-derived
cell line, SGHEC-7, undergoes apoptosis in response to
TRAIL stimulation, and that spiral artery endothelial cells
express TRAIL-R2 at term (Keogh and Cartwright 2006,
unpublished observations).
The ability of TRAIL to cause SMC death by apoptosis is
supported by several lines of evidence. Addition of rhTRAIL
to HASMC cultures increased apoptosis in a concentration-
dependent manner and was inhibited by pretreatment of cells
with a pan caspase inhibitor. Furthermore, increased PARP
cleavage was observed in response to rhTRAIL. In agreement
with our findings, another study demonstated that incubation
of HASMC with rhTRAIL for 24 hours induced significant
apoptosis and PARP cleavage.29 Other work has reported that
TRAIL is without effect on human vascular SMC.23 In this
instance the concentrations of TRAIL used are comparable,
however, the time of exposure was limited to 6 hours or less,
which may be insufficient to see significant cell death. It has
been reported that vascular SMC sequester death receptors
within the cytoplasm and that basal cell surface expression is
Figure 6. HASMC apoptosis induced by primary CTB is blocked
by a TRAIL-R1:Fc construct and TRAIL is expressed by primary
CTB and HASMC. A, Contact cocultures of HASMC alone (E) or
HASMC and primary cytotrophoblasts (CTB, ‚) were treated with a
TRAIL-R1:Fc construct (Œ, as indicated) and then monitored by
time-lapse microscopy. The time point at which cells underwent
apoptosis was scored. A, Time course of HASMC apoptosis. B, %
apoptotic HASMC after 60 hours of coculture. *P0.001, repeated
measures ANOVA, Bonferroni’s posthoc test (meanSEM, n3).
C, TRAIL expression by HASMC in the presence and absence of
primary CTB was determined by immunoblot analysis. HASMC
lysates were prepared at 24 and 60 hours from noncontact cocul-
tures of primary CTB and HASMC. A representative auto-
radiograph is shown. D, Primary cytotrophoblast (CTB) 48 hours
postisolation were assessed for cell-surface TRAIL expression by
flow cytometry. The histograms show unpermeablized cells labeled
with isotype control IgG (gray shading) or anti-hrTRAIL (open histo-
grams). A representative from n4 experiments is shown.
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relatively low.32 Prolonged exposure to an apoptotic ligand
may be required to allow sufficient receptors to be trafficked
to, or expressed on, the cell surface to see a significant
increase in apoptosis. A recent article has demonstrated that
SMC are sensitized to Fas L-stimulated apoptosis by IFN-,
which causes Fas to be trafficked to the cell surface.33
Another important consideration is that apoptosis is a slow
process involving individual cells and thus proceeds in an
asynchronous manner. DNA fragmentation and changes in
the cellular ultrastructure are estimated to occur at least 12 to
14 hours from an initial stimulus.34 End point analysis such as
TUNEL staining may only capture a few apoptotic cells at
any one point, giving an impression that TRAIL has no effect.
By using time-lapse microscopy, a cumulative picture of how
apoptosis proceeds can be obtained. While at any single time
only a few cells may undergo apoptosis, by following a
population it is possible to build a time course that shows the
true effect of TRAIL, in this case on HASMC death. Our
observation that TRAIL-R1 and -R2 are only expressed in a
subset of spiral artery SMC in the first trimester placental bed
imposes further spatial and temporal restrictions on TRAIL-
induced apoptosis, thus helping to maintain vessel integrity
during the remodeling process.
TRAIL was identified as a candidate for involvement in
trophoblast-induced SMC apoptosis as it is produced by
trophoblast. TRAIL protein immunoreactivity was detected in
the cytotrophoblast, in sections from human placenta at 8
weeks gestation,14 and in the syncytiotrophoblast of first
trimester placenta.15 TRAIL mRNA has been detected in the
Jar and JEG-3 trophoblast cell lines,15 however, another study
by this group failed to detect a TRAIL mRNA transcript in
primary CTB,16 in contrast to our own data. Two differences
in the cell isolation procedure may have contributed to this
result. We isolated first trimester CTB and cultured them on
Matrigel to promote differentiation to an extravillous pheno-
type, whereas Phillips et al measured TRAIL mRNA imme-
diately postisolation in CTB isolated from term placenta.
The ELISA and flow cytometry data demonstrate that
TRAIL is expressed as the cell-associated form in first
trimester CTB. An additional observation in support of this is
the direct interaction preceding apoptosis of HASMC, seen in
the video sequence and the images captured from it. As
apoptotic ligands such as TRAIL and FasL can be membrane
bound or soluble, this suggests that, in the case of TRAIL, the
cell-associated form may be the predominant form involved
in initiating apoptosis. It is possible that the soluble form may
be liberated in vivo and make a contribution to TRAIL-
dependent apoptosis. Cleavage of TRAIL is initiated by
cysteine proteases, of which the vessel wall is a rich source.35
When trophoblast encounter SMC in the vessel wall, it is
therefore possible that there is a localized release of soluble
TRAIL. Furthermore, the results presented do not exclude the
possibility that in utero, CTB may stimulate resident vascular
cells to produce apoptotic factors, nor do they exclude the
possibility that other cells present within the placental bed,
such as macrophages or uterine natural killer cells, may
release soluble TRAIL that could contribute to SMC apopto-
sis and vessel remodeling.
An immunological role for TRAIL in human pregnancy is
the only one described to date. The feto-placental unit is a
semi-allograft which must use mechanisms to prevent attack
from maternal immune cells. The killing of activated lym-
phocytes by trophoblast via a TRAIL-dependent mechanism
has been proposed to contribute to the attainment of immune
tolerance by the fetus.15,36 We propose that another physio-
logical role in pregnancy can now be assigned to TRAIL, that
is, an involvement in the mechanisms underlying remodeling
of uterine spiral arteries.
This study shows for the first time that primary first
trimester CTB and extravillous trophoblast in situ express the
apoptotic cytokine TRAIL, and that CTB use the TRAIL
pathway to induce SMC apoptosis. These findings are signif-
icant on two levels. First, the results demonstrate a role for
TRAIL under normal physiological conditions. This is im-
portant as the potential use of TRAIL as a therapeutic agent
relies on detailed knowledge of its actions in a nonpathologi-
cal state. Secondly, in addition to its immunological role, a
new function can be ascribed to TRAIL in human pregnancy,
that is, as a contributor to SMC loss during remodeling. The
demonstration that first trimester CTB use a TRAIL-
dependent mechanism to induce SMC death further defines
the mechanisms that underlie vessel remodeling in normal
pregnancies. Elucidating the fundamental elements of this
remodeling process is critical, because defects in vessel
remodeling have been identified in pathological complica-
tions of pregnancy that compromise both maternal and fetal
health. To develop treatments for compromised pregnancies it
is essential to understand the basis of the vascular changes
that occur in normal pregnancy.
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Figure 7. rhTRAIL induces apoptosis of
arterial smooth muscle cells in situ. Sec-
tions from a denuded spiral artery per-
fused with (A) Control medium or (B and
C) 0.5 g/mL rhTRAIL. Vessels were tied
off following perfusion and cultured for 24
hours before being frozen, cryosectioned
and stained. TUNEL-positive cells are
labeled with FITC (green) and medial SMC
are stained for smooth muscle actin (red).
Scale bar100 m. Pictures are represen-
tative of n3 independent experiments.
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